Back to results
US 10,744,168 B2Granted
Genetically modified probiotic for the treatment of phenylketonuria (PKU) disease
AssigneeUniversity of North Texas
InventorsKatherine Durrer, Michael Allen, Ione Hunt von Herbing
Life of this patent
Estimating the term…
Abstract
A GMP adapted to provide the PAL gene for the treatment of PKU when administered orally. The GMP of the present invention may include a probiotic, a PAL gene to be expressed using the probiotic, wherein the PAL gene is functionally attached to a promoter and a ribosome binding site, and may be codon-optimized for expression in a certain host organism. A method of treating the metabolic disease of PKU by oral administration and ingestion of a GMP is also provided.
Claims7
A composition for treating phenylketonuria, comprising:
- a probiotic bacterium from the Lactobacillus genera selected from the group consisting of Lactobacillus acidophilus, Lactobacillus brevis, Lactobacillus casei, Lactobacillus plantarum, and Lactobacillus reuteri, wherein the probiotic bacterium is genetically modified to express an exogenous nucleotide sequence encoding a functional phenylalanine ammonia-lyase (PAL) enzyme protein, and wherein the nucleotide sequence encoding the phenylalanine ammonia-lyase (PAL) comprises SEQ ID NO:15.
A composition for treating phenylketonuria, comprising:
- a probiotic bacterium, wherein the probiotic bacterium is Lactobacillus acidophilus, wherein the probiotic bacterium is genetically modified to integrate an exogenous nucleotide sequence encoding a functional phenylalanine ammonia-lyase (PAL) enzyme protein into the chromosome of the probiotic bacterium, wherein the probiotic bacterium expresses the nucleotide sequence encoding the phenylalanine ammonia-lyase (PAL), and wherein the nucleotide sequence encoding the phenylalanine ammonia-lyase (PAL) comprises SEQ ID NO:
- 15.
Dependencies are inferred from the claim text.